Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2012-12-05 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
关于转让部分内蒙古银宏干细胞生命科技投资有限公司股权过户完成的公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement regarding the completion of the transfer of a portion of equity in a subsidiary company. It mentions the transfer of 40% equity and the completion of the registration process. There is no financial data, no detailed report, no meeting materials, or voting results. It is an update on a capital transaction related to shareholding in a subsidiary. This fits best under Capital/Financing Update (CAP) as it relates to changes in capital structure or equity holdings. The document length is short and it is not a report publication announcement or regulatory filing. Therefore, the classification is CAP with high confidence.
2012-12-05 Chinese
重大诉讼终结执行公告
Legal Proceedings Report Classification · 100% confidence The document is an announcement regarding the conclusion of a significant legal proceeding involving the company and its subsidiary. It references court decisions, execution rulings, and legal enforcement actions. There is no financial data, no report attached or referenced as being published, and the content focuses solely on legal matters. Therefore, this document fits the category of Legal Proceedings Report (LTR).
2012-12-04 Chinese
资产评估报告
Audit Report / Information Classification · 95% confidence The document is a detailed asset valuation report for the equity held by Heze Biotechnology Co., Ltd. in Inner Mongolia Yinhong Stem Cell Life Science and Technology Investment Co., Ltd. It includes an asset appraisal report issued by Beijing Longyuan Zhibo Asset Appraisal Co., Ltd., with a registration number and dated November 29, 2012. The report contains comprehensive sections such as the appraiser's statement, purpose, scope, valuation methods (asset-based and income approaches), financial data, shareholder structure, legal and regulatory references, and detailed valuation results. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. It is not an annual report, earnings release, or management discussion but a standalone asset appraisal report related to a proposed equity transfer. This fits the definition of an Audit Report / Information (AR), which includes standalone audit or valuation reports and applied accounting principles, excluding full annual reports. Therefore, the correct classification is AR with high confidence. 9M 2012
2012-12-03 Chinese
：内蒙古银宏干细胞生命科技投资有限公司审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an audit report from Reanda accounting firm for Inner Mongolia Yinhong Stem Cell Life Science Investment Co., Ltd. It includes detailed financial statements such as balance sheet, income statement, cash flow statement, and statement of changes in equity for the period ending October 31, 2012. The document also contains extensive notes on accounting policies, financial instruments, and other disclosures typical of an audit report. The presence of an auditor's opinion section and detailed financial data confirms this is a standalone audit report rather than a full annual report or other filing. The document length is substantial (15,000 characters) and contains actual financial data, so it is not a mere announcement or certification. Therefore, the appropriate classification is Audit Report / Information (AR). 9M 2012
2012-12-03 Chinese
关于转让部分内蒙古银宏干细胞生命科技投资有限公司股权的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the transfer of a portion of equity in a subsidiary company (Inner Mongolia Yin Hong Stem Cell Life Technology Investment Co., Ltd.) by the company's subsidiary Heze Biology Technology Co., Ltd. It details the transaction terms, parties involved, financial data, and the impact on the company. The document includes information about the board meeting approval but does not contain full financial statements or comprehensive financial performance data. It is a corporate announcement about a capital transaction (equity transfer) rather than a full financial report or earnings release. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 4216 characters, which is sufficient for a detailed announcement but not a full report. No indication that this is a report publication announcement or regulatory filing. Hence, the classification is CAP with high confidence.
2012-12-03 Chinese
关于子公司和泽生物科技有限公司签订《房屋租赁合同》关联交易公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a related-party transaction involving a subsidiary and a related company, specifically about signing a new property lease contract. It details the transaction terms, related parties, approval procedures, and independent directors' opinions. There is no financial statement, earnings data, or report attached or referenced as being published. The document is a formal disclosure of a related-party transaction, which is a regulatory announcement. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is not a report publication announcement since it contains substantive transaction details. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and disclosures that do not fit other categories.
2012-12-03 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.